Literature DB >> 12799927

[Opioid therapy in Austria: results and analysis of a survey].

G Bernatzky1, W Pipam, G Pinter, G Mitterschiffthaler, R Likar.   

Abstract

INTRODUCTION: Many causes are given as the main reason for inadequate pain therapy. The objective of our study was to demonstrate the current position of doctors in general practice all over Austria who prescribe prescriptions.
METHODS: A total of 5,359 questionnaires were sent out to general practitioners in all federal states of Austria. These questionnaires contained 21 main questions on subjects relevant to pain therapy.
RESULTS: On average, 16% of all general practitioners returned the questionnaires; 89.3% of these are acquainted with the WHO graduated scale, 87% have prescribed strong opioids. Old prejudices such as concerns about the side effects are hardly to be found now. Modern therapy strategies are used.
CONCLUSION: Based on the data at hand, pain therapy for patients should be excellent. The reality, however, is somewhat different. The large number of doctors who did not reply makes it enormously difficult to make a statement about the position of pain therapy in Austria.

Entities:  

Year:  1999        PMID: 12799927     DOI: 10.1007/s004829900004

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  3 in total

1.  [Physicians' knowledge on cancer pain therapy : Comparison of palliative care and prehospital emergency physicians in training].

Authors:  C H R Wiese; C L Lassen; J Vormelker; N Meyer; A F Popov; B M Graf; G G Hanekop; S Wirz
Journal:  Schmerz       Date:  2011-12       Impact factor: 1.107

Review 2.  [Psychological pain therapy and opioids -- a contradiction?].

Authors:  P Nilges
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

3.  [Pain experience and pain therapy of tumor patients in the view of general practitioners].

Authors:  H Janig; W Pipam; S Lastin; R Sittl; G Bernatzky; R Likar
Journal:  Schmerz       Date:  2005-04       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.